Clomid (clomiphene citrate) is not an aromatase inhibitor. It is a selective estrogen receptor modulator, or SERM, which works through a completely different mechanism. The confusion is understandable because both Clomid and aromatase inhibitors like letrozole are prescribed for the same purpose: stimulating ovulation in women struggling to conceive. But they achieve this goal in fundamentally different ways, and those differences matter for outcomes and side effects.
How Clomid Actually Works
Clomid blocks estrogen receptors in the brain, specifically in the hypothalamus and pituitary gland. When these receptors are blocked, the brain is essentially tricked into thinking estrogen levels are low, even when they aren’t. In response, it ramps up production of two hormones that signal the ovaries to develop and release eggs: follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
The key detail is that Clomid doesn’t reduce the amount of estrogen in the body. It just prevents the brain from detecting it. Estrogen is still circulating, and Clomid’s receptor-blocking activity extends beyond the brain to other tissues, including the uterine lining and cervical mucus glands. This is where its main drawbacks come from.
How Aromatase Inhibitors Differ
Aromatase inhibitors like letrozole (brand name Femara) work one step earlier in the process. They block the enzyme aromatase, which converts androgens into estrogen throughout the body. This causes an actual drop in estrogen levels, and the brain responds naturally by increasing FSH and LH to stimulate the ovaries.
Once the drug clears the system, estrogen levels recover on their own as the ovarian follicles grow and produce it. Because letrozole has a half-life of about two days compared to Clomid’s two weeks, it’s out of the body well before ovulation occurs. That means it doesn’t interfere with estrogen’s effects on the uterine lining or cervical mucus during the critical window when an embryo would need to implant.
Why the Difference Matters for Fertility
Clomid’s long-lasting estrogen-blocking effect is its biggest clinical limitation. Because it lingers in the body, it can thin the endometrial lining and reduce cervical mucus quality, both of which are essential for conception. In some women, the uterine lining becomes too thin for an embryo to implant successfully, even though ovulation occurred normally. This is sometimes called “Clomid failure,” defined as either a failure to ovulate or a thin endometrial lining that prevents implantation.
Letrozole, by contrast, consistently produces thicker endometrial linings and lower preovulatory estrogen peaks. A large meta-analysis of 33 randomized controlled trials involving nearly 5,000 women with polycystic ovary syndrome (PCOS) found that letrozole led to an 18% higher ovulation rate and a 54% higher live birth rate compared to Clomid. These are significant margins, and they’re a major reason many fertility specialists now favor letrozole as a first-line treatment for ovulation induction.
Another practical advantage of aromatase inhibitors: they carry a lower risk of multiple pregnancies. Clomid’s prolonged presence in the body can cause the ovaries to develop several mature follicles simultaneously, increasing the chance of twins or higher-order multiples.
Side Effects Compared
Both drugs can cause hot flashes, headaches, and mild abdominal discomfort, but Clomid has a distinct side effect profile tied to its estrogen-blocking activity. Reported side effects include ovarian enlargement (about 14% of users), hot flashes (10%), abdominal discomfort (6%), and nausea (2%). About 1.5% of women experience visual disturbances, which can include shimmering vision, flashes of light, blurred or double vision, blind spots, light sensitivity, and lingering afterimages. These visual symptoms are unique to Clomid and don’t occur with aromatase inhibitors.
Letrozole’s side effects tend to be milder overall, partly because the drug clears the body so quickly. Its main advantage is the absence of anti-estrogenic effects on the uterus and cervix, which also means less intensive monitoring is typically needed during treatment cycles.
Clomid’s Role in Men
Clomid is also used off-label in men with low testosterone, which adds to the confusion about its drug class. In men, Clomid’s estrogen-blocking action at the brain level triggers increased LH and FSH production, which stimulates the testes to produce more testosterone and sperm. This is a different approach from testosterone replacement therapy, which actually suppresses sperm production.
The testosterone increases can be substantial. Across multiple studies, men taking Clomid typically see their testosterone levels roughly double. One study documented a mean increase from 227 to 573 ng/dL, a 107% jump. Another found levels rising from 248 to 610 ng/dL, a 146% increase. Men in these studies generally reported improvements in energy, libido, mood, and cognitive function within about six weeks.
Aromatase inhibitors have also been used off-label in men for similar purposes, but through a different mechanism: by reducing the conversion of testosterone to estrogen, they allow testosterone levels to rise. The two drug classes are sometimes even used together in male fertility protocols, which further blurs the line for people researching them online.
Which One Your Doctor Might Recommend
For women with PCOS or unexplained infertility, letrozole has increasingly become the preferred first-line option based on the live birth data. Clomid remains widely used, partly because it has a longer track record (it’s been available since the 1960s) and partly because some clinics and insurance plans still default to it. Both are taken orally, typically for five days early in a menstrual cycle.
For men with low testosterone who want to preserve fertility, Clomid is more commonly prescribed because of the larger body of evidence supporting its use. The choice between these medications depends on individual circumstances, but they are distinct drug classes with different mechanisms, different side effect profiles, and in some contexts, meaningfully different success rates.